Literature DB >> 20861606

The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration.

Lucía Pérez-Carmona1, Ingrid Aguayo-Leiva, Carmen González-García, Pedro Jaén-Olasolo.   

Abstract

The quadrivalent human papillomavirus (qHPV) vaccine, the first vaccine for use in the prevention of cervical cancer and condyloma acuminatum, was approved in June 2006. In 2008, the mass media reported suspected links between the qHPV vaccine and serious adverse events; however, several studies have found that the vaccine is safe and the main adverse events are mild local reactions. Erythema multiforme (EM) is an acute self-limited cutaneous or mucocutaneous syndrome characterized by the abrupt onset of symmetric target lesions. The clinical manifestations and histological features of EM, Stevens-Johnson syndrome and toxic epidermal necrolysis show considerable overlap, and they are classically considered to represent a spectrum of skin disorders. We present a case of EM following qHPV vaccination to review the cutaneous side effects of this vaccine and the possibility of more serious side effects with the administration of booster doses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861606     DOI: 10.1159/000319852

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  3 in total

1.  Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018.

Authors:  G Gross; N Becker; N H Brockmeyer; S Esser; U Freitag; M Gebhardt; L Gissmann; P Hillemanns; H Grundhewer; H Ikenberg; H Jessen; A Kaufmann; S Klug; J P Klußmann; A Nast; D Pathirana; K U Petry; H Pfister; U Röllinghof; P Schneede; A Schneider; E Selka; S Singer; S Smola; B Sporbeck; M von Knebel Doeberitz; P Wutzler
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

2.  Toxic epidermal necrolysis after yellow fever vaccination.

Authors:  Thaís Bologna Flora; Célia Antônia Xavier de Moraes Alves; Fernanda de Mattos Pereira Barucci; Camila Bonati Mattos
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

3.  An extremely rare mucocutaneous adverse reaction following COVID-19 vaccination: Toxic epidermal necrolysis.

Authors:  Masoud Mardani; Sayna Mardani; Zahra Asadi Kani; Atousa Hakamifard
Journal:  Dermatol Ther       Date:  2022-03-09       Impact factor: 3.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.